A group of proteins known as toll-like receptors (TLRs) are essential components of the innate immune system. They are single, membrane-spanning, non-catalytic receptors that recognize structurally conserved molecules derived from microbes and are typically expressed in sentinel cells like macrophages and dendritic cells. Once these microbes have gotten past physical barriers like the skin or mucosa of the gastrointestinal tract, TLRs recognize them and trigger immune cell responses.
TLR1 through TLR13 are among the TLRs, along with TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, TLR11, TLR12, and TLR13. Toll-Like Receptors (TLRs) are involved in both the detection of endogenous danger signals and the early innate immune response to encroaching pathogens. TLRs are homologs of the Drosophila Toll protein, which was found to be crucial for defense against microbial infection. They are evolutionarily conserved receptors. TLRs identify pathogen-associated microbial patterns (PAMPs), which are only expressed by microbial pathogens and are highly conserved structural motifs.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V51012 | CL-104773 | 802980-92-3 | TLR2 antagonists; JAK2 inhibitor |
|
V74355 | Cobitolimod | 1226822-98-5 | Cobitolimod is a DNA oligonucleotide agonist of TLR-9 with anti-inflammatory activity. |
|
V74354 | Cobitolimod sodium | 1527479-55-5 | Cobitolimod sodium is a DNA oligonucleotide agonist of TLR-9 with anti-inflammatory activity. |
|
V51027 | CU-115 | 2471982-20-2 | CU-115 is a disabling TLR8 antagonist (IC50=1.04 µM) and shows activity against TLR8 and TLR7 (IC50=>50 µM). |
|
V3815 | CU-CPT-8m | 125079-83-6 | CU-CPT-8m is a novel, potent and specific antagonist ofToll-like receptor 8 (TLR8)with immunomodulatory effects. |
|
V3816 | CU-CPT-9a | 2165340-32-7 | CU-CPT-9a, an analog ofCU-CPT-8m, is a potent and specificantagonist/inhibitor of TLR8 (Toll-like receptor 8) (IC50 = 0.5 nM) with the potential to be used for treating autoimmune diseases. |
|
V3817 | CU-CPT-9b | 2162962-69-6 | CU-CPT-9b, an analog ofCU-CPT-8m and CU-CPT-9a, is a specificantagonist of TLR8 (Toll-like receptor 8) with IC50 of 0.7 nM. |
|
V3818 | CU-CPT17e | 2109805-75-4 | CU-CPT17e is a multi-TLR (Toll-like receptor) agonist that activates TLR3, TLR8, and TLR9 with immunomodulatory activities. |
|
V18880 | CU-T12-9 | 1821387-73-8 | CU-T12-9 (CU T12-9; CU-T129) is a novel and potent TLR1/2 (Toll-like receptor) agonist with potential immunemodulatory and antitumor effects. |
|
V74352 | DB-3-291 | 2769753-64-0 | DB-3-291 is a potent and specific CSK degrader with Kd of 1 nM. |
|
V37618 | DSR-6434 | 1059070-10-8 | DSR-6434 (DSR6434) is a novel and selective Toll-like receptor 7 (TLR7) agonist with antitumor effects. |
|
V83241 | E-6742 | 1700609-11-5 | E-6742 is a novel TLR7/8 inhibitor being developed for the treatment of systemic lupus erythematosus (SLE). |
|
V74378 | E104 | 1610431-21-4 | E104 (compound 1) is a potent and specific TLR7 agonist. |
|
V20341 | E6446 | 1219925-73-1 | E6446 is a potent, orally bioavailable TLR7 and TLR9 antagonist for the study of harmful inflammatory responses. |
|
V20340 | E6446 HCl | 1345675-25-3 | E6446 is a synthetic antagonist of nucleic acid-sensing TLRs. |
|
V74372 | Enpatoran hydrochloride (M5049 hydrochloride) | 2101945-93-9 | Enpatoran (M5049) HCl is a potent, orally bioactive TLR7/8 inhibitor (antagonist) with IC50s of 11.1 nM and 24.1 nM in HEK293 cells, respectively. |
|
V53258 | Eritoran | 185955-34-4 | Eritoran is a Toll-like receptor 4 (TLR4) antagonist. |
|
V79421 | FITC-labeled Agatolimod sodium | FITC-labeled Agatolimod (sodium) is a class B CpG ODN and a TLR9 agonist. | |
|
|
V77015 | FITC-labeled ODN 1018 sodium | FITC-labeled ODN 1018 (sodium) is a TLR9 agonist. | |
|
|
V79422 | FITC-labeled ODN 1585 sodium | FITC-labeled ODN 1585 (sodium) is a class B CpG ODN and a TLR9 agonist. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
